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The Psoriasis Area and Severity Index (P ASI) is used by der-
rnatologic investigators to assess psoriasis disease severity. 
P .ASI measures are time-consuming and require trained per-
sonnel. We developed and evaluated a structured PASI-like 
instrument for self-measurement of psoriasis disease severity 
for use in future large-scale epidemiologic studies. The in-
strument consisted of a silhouette of a body for patients to 
shade in affected areas and of three modified visual analog 
scales for recording the redness, thickness, and scaliness of an 
average lesion. The resulting "patient PASI" score was com-
pared to investigator PASI measurements in 43 patients with 
mild to severe psoriasis. Patients and investigator also 
recorded a subjective global severity score. The patient PASI 
score was highly predictive of the investigator PASI score 
(r2 = 0.71, P < 0.0001) and the investigator global score 
C linical investigators frequently measure psoriasis dis-ease severity with the Psoriasis Area and Severity Index (PASI). Since its development in 1978 [1], this instrument has been used throughout the world by investigators interested in clinical aspects of disease 
severity [2- 5]. Although clinicians display variability in assessing 
severity of invol vement [6] , PAS! measures of erythema, induration, 
and scale correlate well with objective assessment by transepidermal 
water loss measurement and chromameter assessment. * 
P AS! measures are time-consuming and require trained person-
nel. Therefore, its application to large-scale epidemiologic research 
on psoriasis disease severity is limited. No method exists that allows 
patient~ or clini~al study p~ti.cipants to evaluate the physical char-
acteriStiCS of their own conditIOn. We developed a structured PASI-
like instrument to test the hypothesis that patients can accurately 
assess the severity of psoriasis . 
MATERIALS AND METHODS 
Participants in this study were patients presenting to The Bowman Gray 
School of Medicine of Wake Forest University Psoriasis and Skin Treatment 
Center who had received the diagnosis of psoriasis vulgaris . We developed a 
one-page instrument ("patient PAS!"), consisting of two parts, for patients 
to measure their disease severity. Three modified 120-mm visual analog 
scales (VAS) enabled patients to describe the color, induration, and scaliness 
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(r2 = 0.37, P < 0.0001). The patient global score was also 
predictive of the investigator PASI (r2 = 0.18, P < 0.0053) 
and the investigator global score (r2 = 0.10, P < 0.044), but 
these relationships exhibit wide predicted confidence inter-
vals . Following the initial evaluation by 18.4 ± 9.1 d of 
therapy, one-way t tests for paired samples (pre and post) 
showed significant improvements in the patient P ASI (p < 
0.003) and investigator PASI (p < 0.05). We conclude that 
although patients' overall scores may not allow for accurate 
prediction of clinical disease severity in a single individual, 
this structured instrument facilitates prediction of psoriasis 
disease severity in a population. Key words: Psoriasis Area and 
Severity Index (PASI) /structured instrument/psoriasis. ] Invest 
Dermatol1 02:967 - 969, 1994 
of an "average" psoriatic lesion. On each VAS, extremes and intermediate 
levels were labeled. For instance, the V AS for erythema contains the follow-
ing word descriptions: no redness, slight pink, pink, red, and dark red. 
Similarly, the induration V AS contained the descriptions no thickness, feels 
firm, raised, thick, and very thick; and scaliness VAS contained the descrip-
tions no scale, slight scale, scaly, flaky, and very flaky. A modified 120-mm 
VAS assessed the patients' global psoriasis severity score. 
As in the original PASI score (1], the patient PAS! weights the involve-
ment of the head, upper extremities, trunk, and legs as 10%, 20%, 30%, and 
40% of the total body surface area, respectively. To estimate the surface area 
involved, a line-drawing silhouette of the front and back of a body was 
presented to patients and they were instructed to shade in the areas currently 
affected by psoriasis. Based on the silhouette shading, a single investigator 
who had not evaluated these patients (AF) assigned a numeric value of 0 to 6 
corresponding to 0 to 100% involvement for each of the following four 
areas: head, upper extremities, trunk, and lower extremities. With the ex-
ception that 0% involvement was scored as a zero instead of a one, these 
site-specific area scores correspond to the original PAS! [1]. Each 120-mm 
VAS was normalized to a continuous equivalent of the five-point scale (0 to 
4) and was used for all areas of involvement. The Patient PASI was calculated 
from the equation below: 
Patient PASl = [(0.1. AH) + (0.2' Au) + (0.3' AT) + (0.4 ' Ad] 
[0.0333 • (VASE + VAS, + VASs )] 
where AH = head area score, Au = upper extremity area score, AT = trunk 
area score, AL = lower extremities score, V AS. = VAS erythema score 
(mm), VAS, = VAS induration score (mm), and VASs = VAS scale score (mm). 
On the same day that the patient completed the instrument, one of two 
clinicians blind to the patient PAS! rating (JV or SF) recorded a PAS! score 
[1] ("investigator PASI") on the patients. The extent of involvement of each 
body area was scored on a 1 to 6 scale. Each area was also assigned a 0 to 4 
nutneric score corresponding to "none," "slight," umoderate." "severe," 
and "extraordinarily severe" for erythema, infiltration, and desquamation. 
Clinicians were then asked to provide a global assessment on a 100-mm 
V AS. The investigator PASl was calculated from separate area and severity 
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Figure 1. Investigator and patient PAS I scores by sex_ 
measures as previously described [1]. The patients' overall score was normal-
ized to correspond to the investigators' 1 OO-mm VAS. 
To evaluate the instrument as a measure of clinical response, a subsample 
of the patients were re-evaluated in an identical fashion followin~ various 
modalities of treatment including psoriasis day care, system therapies, ultra-
violet light treatment, and topical care. Data processing and statistical analy-
sis were performed with the SAS system (Cary, NC). 
RESULTS 
Twenty-three ~omen and 20 men with ages ranging from 21 t~ 74 
years (mean ± SD = 44.7 ± 13.4) were assessed. Mean patient 
PASI scores were 11.1 ± 10.7 whereas mean investigator PAS I 
scores were 8.1 ± 6.6. Male and female scores are plotted in Fig 1. 
We performed linear regressions for investigator PASIon pat!ent 
PASI, patient global score, and investigator global score, and patient 
PASI was the strongest predictor. Investigator PASI had a signifi-
cant regression on patient PASI (p < 0.0001) and 71 % of the varia-
tion in investigator PAS I was explained (r2 = 0.71). In comparison, 
the regressions on the patient global score explained 18% of the 
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Figure 2. Linear regression (solid line) with 95% confidence intervals (dot-
led lilies). 
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Figure 3. The patient overall score has been normalized to a 100-m~ VAS. 
Linear regression (solid line) with 95% confidence intervals (dotted l/tles) . 
variation in investigator PASI (r2 = 0.18, P < 0.0053), and investi-
gator global score explained 10% (r2 = 0.1, P < 0.044). Scatterplots 
of the data with the regression lines and confidence intervals are 
displayed in Figs 2, 3, and 4. 
The regression of the patient on investigator P ASI scores has an 
intercept of2.3 ± 0.8 and a slope of 0.51 ± 0.05. In this sample, the 
ratio of the investigator P ASI to patient PASI had no significant 
regression on investigator PASI (p = 0.8), so this relationship does 
not depend on disease severity. A multiple regression of the ratio of 
the investigator PASI to patient PASI showed 110 significant effects 
of age (p = 0.3) or gender (p = 0.5) . 
To test the hypothesis that patient PAS I may be used to follow 
alterations in disease status, re-evaluation of a subset of patients 
occurred a mean of 18.4 ± 9.1 d following initia1 evaluation. Fif-
teen patients (nine women and six men) decreased their investigator 
and patient PASI scores, respectively, to 7.3 ± 5.7 and 5.9 ± 4.7. 
These changes in scores are plotted on Fig 5. Over the treatment 
period, one-way t tests for paired samples (pre and post) showed 
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Figure 4. Linear regression (solid lille) with 95% confidence intervals (dOl-
led lilies). 
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Fig11':e S. Patient and investigator PAS! scores before and after treatment. 
Each letter corresponds to a different subject. 
significant improvements in the patient PASI (p < 0.003) and in-
vestigator PAS I (p < 0.05). 
DISCUSSION 
The instrument we developed differs from the P ASI in two major 
respects. First, untrained patients administer the instrument to 
themselves. Second, patients evaluate an "average" psoriatic lesion 
for erythema, induration, and scale instead of separately scoring 
lesional severity in each body area. Despite these differences, our 
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analysis suggests that patient PAS! is a good predictor of investigator 
P ASI, and that the ratio of patient to investigator P ASI is not af-
fected by the patient characteristics collected in this study. Thus, 
although there may be substantial errors in the estimation of disease 
severity for individual patients, patient P ASI should be a good pre-
dictor of average disease severity and changes in disease severity in 
patient populations. In contrast to the excellent predictive value of 
the patient PASI, we found that the patients' global severity scores 
had unacceptably wide predicted confidence intervals. 
In future studies, patient P ASI may be used as a tool for estimating 
psoriasis disease severity and for documenting response to therapeu-
tic intervention. For the purposes of identifying psoriasis disease 
severity economically or when trained personnel are not available, 
e.g., a written questionnaire mailed to known psoriasis patients, this 
measure may prove to be a useful tool. 
The P ASI score and our patient P ASI do not assess all aspects of 
psoriasis morbidity. Disability, social stigmatization, and musculo-
skeletal morbidity are key aspects of psoriasis morbidity relevant to 
patient care that are not measured by a disease-severity index such as 
the PAS!. One can hypothesize that thin plaques on the face of a 
teenage woman may be perceived by the patient as having great 
morbidity, but the investigator PASI score would be quite low. 
Nevertheless, we have demonstrated that a population of patients 
can accurately assess their cutaneous psoriasis severity using a struc-
tured instrument. 
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